CuraSen to bring new Alzheimer’s drug into trial in 2024

US-based CuraSen Therapeutics plans to initiate a first-in-human clinical trial with new neurodegenerative disease drug CST-3056 in Q4 2024, CEO Dr Anthony Ford told Clinical Trials Arena.

The biopharma company recently received $5.8m in funding from the Alzheimer’s Drug Discovery Foundation. The funds will cover nonclinical safety studies, which are expected to begin in early 2024, and the first Phase I clinical trial later in the year, Ford explained.